Afuco™ Anti-Human CD19 ADCC Therapeutic Antibody (MDX-1342), ADCC Enhanced
Anti-CD19 ADCC Enhanced Antibody (MDX-1342) is an ADCC enhanced antibody produced by our Afuco™ platform. MDX-1342 is a fully human monoclonal antibody (HuMAb) with enhanced antibody-dependent cellular cytotoxicity (ADCC) effector function, targeting CD19-membrane receptor which is highly expressed on malignant chronic lymphocytic leukemia (CLL) cells.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-104CL |
| Pricing | Inquiry |
| Host | Human |
| Target | CD19 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Storage | Can be stored at 4°C. For long term storage, aliquot and store at -20°C. Avoid repeated freezing and thawing cycles. |